Chai Discovery Reaches $1.3 Billion Valuation After Raising $130 Million in Series B Funding
Chai Discovery, a San Francisco-based biotechnology startup founded in 2024, has rapidly emerged as one of the most closely watched AI-driven drug discovery companies, attracting substantial venture capital backing and culminating in a major valuation milestone with its latest funding round. The company’s cutting-edge approach combines advanced artificial intelligence models with molecular design to accelerate the discovery of therapeutic drugs and antibodies, a strategy that has resonated strongly with investors across the technology and healthcare sectors.
In December 2025, Chai Discovery announced the successful completion of a $130 million Series B funding round, catapulting the company’s valuation to approximately $1.3 billion and effectively securing its place among AI-powered biotech unicorns. The round was co-led by General Catalyst and Oak HC/FT, two of the most prominent investors in technology and healthcare innovation. In addition to the co-lead investors, the funding round saw continued participation from existing backers and strategic supporters including Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, and SV Angel, while new investors such as Glade Brook and Emerson Collective also joined the cap table. With this infusion of capital, Chai Discovery’s total funding has now exceeded $225 million since its inception.
The Series B financing reflects growing confidence from both technology and life sciences investors in Chai Discovery’s mission to transform traditional drug discovery through AI. The company’s platform focuses on predictive molecular modeling and de novo antibody design, enabling researchers to computationally design novel molecules with specific therapeutic properties. Its latest generation of models has demonstrated meaningful improvements in accuracy and efficiency compared with earlier computational methods, reinforcing investor belief in the scalability and commercial potential of its technology.
This funding milestone builds on strong momentum from an earlier round. In August 2025, Chai Discovery raised a $70 million Series A round led by Menlo Ventures through its Anthology Fund, with participation from a broad group of technology-focused and healthcare investors. That round included backing from Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam. The Series A capital supported the expansion of Chai’s research team, continued development of its AI models, and early engagement with partners across the pharmaceutical and biotechnology industries.
Chai Discovery’s rise comes amid intensifying competition in the AI-augmented drug discovery sector, where startups aim to reduce the time, cost, and uncertainty associated with traditional pharmaceutical research and development. Drug discovery has historically required years of laboratory experimentation and billions of dollars in investment. By shifting much of the early-stage discovery process into computational design, Chai aims to significantly compress development timelines while increasing the probability of success.
The company’s leadership team, composed of founders with deep experience in artificial intelligence, computational biology, and applied research, has played a central role in attracting investor confidence. Under their direction, Chai Discovery has prioritized building foundational models that can be applied broadly across therapeutic areas, positioning the company as a platform rather than a single-asset biotech startup.
Investors backing Chai Discovery represent a mix of venture capital firms, strategic technology players, and healthcare-focused funds, highlighting the cross-disciplinary appeal of its approach. The involvement of organizations deeply rooted in AI research alongside established healthcare investors underscores the belief that machine learning will become a core component of future drug development.
Looking ahead, Chai Discovery plans to use its Series B funding to accelerate product development, expand partnerships, and further refine its AI-driven discovery platform. As artificial intelligence continues to reshape the life sciences industry, Chai Discovery’s funding trajectory signals strong investor conviction in its potential to redefine how new medicines are discovered and designed.
